Complete Genomics Previews Revolocity™ Sequencing System at European Human Genetics Conference 2015

Complete Genomics Previews Revolocity Sequencing System at European Human Genetics Conference 2015

Mater Health Services (Australia) and Radboud University Medical Center (The Netherlands) select first "supersequencer"

MOUNTAIN VIEW, Calif. – June 6, 2015 – Complete Genomics, Inc., a leader in whole human genome sequencing, today announced that Mater Health Services, a leading Australian health services provider, and Radboud University Medical Center in the Netherlands are to become the first customers for the Revolocity sequencing system, the company's new fully integrated "supersequencer." The Revolocity system is being previewed at the European Human Genetics Conference (June 6–9, Scottish Exhibition and Conference Centre [SECC], Glasgow, UK) on June 6, 2015.

In recent years, DNA sequencing and computational technologies have advanced rapidly, throughput has skyrocketed, and the cost of genome sequencing has plummeted. Complete Genomics has been at the forefront of these advances, sequencing more than 20,000 whole human genomes and driving the adoption of next-generation sequencing (NGS) in clinical research. Now Complete Genomics has incorporated its NGS technology and operational knowledge into the Revolocity system — the first truly integrated high-capacity sequencing system for laboratories that demand a cutting-edge genomic facility.

The Revolocity sequencing system is designed to deliver 10,000 whole genome sequences (WGS) a year, and expand to 30,000 WGS per year—surpassing the scalability of any other sequencing solution available today. The Revolocity system also supports whole exome sequencing (WES). It automates DNA purification from a variety of starting materials, including whole human blood and saliva, and then processes samples seamlessly through the library preparation, sequencing, and data analysis phases. The Revolocity system provides high-confidence data on small variants, including SNPs, insertions, deletions, block substitutions as well as CNVs and structural variants.

Mater Health Services in Brisbane, Australia, has chosen to make the Revolocity system the centerpiece of a new purpose-built core facility, opening mid-2016, to provide the first genomics-based clinical diagnostics service in the Australian market. Professor Deon Venter, Mater Director of Pathology said: "Mater Health Services is very excited to be at the forefront of using whole genome sequencing technology to improve thousands of patient outcomes, not just in Australia, but potentially across Asia and Europe. The uses for this technology across the spectrum of acute and preventative medicine are enormous and will be the greatest advance in medical care for decades. Whole genome sequencing can increase the diagnostic yield many times more than conventional genetic tests and also provides important additional information such as which drugs the patient should or should not be given. People that will benefit from this technology will include those with cardiac, neurological and developmental diseases and newborn babies, as well as cancer patients."

Joris Veltman, Professor of Translational Genomics at Radboud University Medical Center (Radboudumc) in Nijmegen, the Netherlands, said: "For clinical research in an academic center like Radboudumc it is very important to obtain a complete solution, from blood to annotated genome. We think the solution offered by Complete Genomics will greatly facilitate the implementation of complex genomics tests. We have worked well with Complete Genomics in the past and are very impressed with the quality of their genome sequencing technology. Radboudumc is very excited to expand its capabilities to perform large-scale exome and genome sequencing with this acquisition.

"Mater Health Services and Radboudumc are regarded as being at the forefront of introducing personalized medicine through improved diagnostics and therapeutics in Australia and Europe. I am therefore delighted they have both chosen the Revolocity system as their core platform. Its high throughput and automated capabilities offer both of these institutions the opportunity to take their genome and exome sequencing capacities to previously unseen levels, enabling them to develop a whole range of new tests," said Complete Genomics CEO, Clifford A. Reid, PhD.

About Complete Genomics

Complete Genomics, a BGI company, is a leader in whole human genome sequencing based in Mountain View, California. Using its proprietary sequencing instruments, chemistry, and software, the company has sequenced more than 20,000 whole human genomes. The company's mission is to improve human health by providing researchers and clinicians with the core technology and commercial systems to understand, prevent, diagnose, and treat diseases and conditions.

About Mater Health Services

Mater Health Services comprises several hospitals, health centres, a world-class medical research institute, and pathology and pharmacy businesses—all with one aim—to provide Exceptional Care.

About Radboud University Medical Center

Radboud University Medical Center is a leading academic center for patient care, education and research, with the mission 'to have a significant impact on healthcare'. Our activities help to improve healthcare and consequently the health of individuals and of society. We believe we can achieve that by providing excellent quality, participatory and personalized healthcare, operational excellence and by working together in sustainable networks.


Complete Genomics: Richard Hayhurst | +44 7711 821 527 | [email protected]

Mater: Jacqueline Hayes | +61 07 3163 2378 | [email protected]

Radboudumc: Pieter Lomans | +31 631970558 | Pieter.lo[email protected]


BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.